Position in GNPX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2
-$7 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#21
of 26 holders
Holding Since
Jun 2023
12 quarters on record
Common Shares in GNPX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nemes Rush Group LLC holds $3,327,523 across 17 Biotechnology names. GNPX ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,579 | $2,771,256 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
|
5,165 | $201,486 | |
| 3 | SLS |
SELLAS Life Sciences Group, Inc.
|
10,000 | $147,600 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
2,000 | $109,880 | |
| 5 | ACAD |
Acadia Pharmaceuticals Inc
|
2,000 | $50,600 | |
| 6 | DNLI |
Denali Therapeutics Inc.
|
700 | $18,004 | |
| 7 | CRMD |
CorMedix Inc.
|
2,000 | $15,700 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
8 | $4,988 |
All Filings in GNPX
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2 | 5 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9 | 5 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $8 | 5 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $42 | 250 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $56 | 250 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $61 | 250 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $212 | 250 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $90 | 250 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $471 | 250 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $744 | 250 | Shares | Sole | 2024-05-15 | |
| 2023-09-30 | $3,950 | 10,000 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $9,490 | 10,000 | Shares | Sole | 2023-08-02 | |
| No filing history on record for this holder in this stock. | ||||||